A 58-year-old man with a 10-year history of type 2 diabetes mellitus and hypertension presents with stable angina. His LDL cholesterol is 145 mg/dL despite lifestyle modifications. Which drug is the first-line choice for primary prevention of atherosclerotic cardiovascular disease in this patient?

Explanation

## First-Line Lipid-Lowering Therapy in Atherosclerosis Prevention **Key Point:** Statins are the gold-standard first-line agents for both primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) due to their potent LDL-lowering efficacy, pleiotropic anti-inflammatory effects, and robust cardiovascular outcome data. ### Mechanism of Statin Action Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. This leads to: - 30–50% reduction in LDL cholesterol - Upregulation of LDL receptors on hepatocytes - Pleiotropic effects: endothelial stabilization, anti-inflammatory action, plaque stabilization ### Evidence Base **High-Yield:** Major trials (4S, WOSCOPS, AFCAPS/TexCAPS, HPS, JUPITER) demonstrate that statins reduce ASCVD events by 20–30% in both primary and secondary prevention across all risk groups. ### Clinical Application in This Patient - Diabetes + hypertension = high ASCVD risk - LDL 145 mg/dL = above goal (target <100 mg/dL for high-risk patients, <70 mg/dL for very high-risk) - Atorvastatin (moderate-to-high intensity statin) is the standard first-line choice ### Comparison with Other Agents | Agent | Role | When Used | |-------|------|----------| | **Atorvastatin** | First-line statin | All patients requiring lipid lowering | | **Ezetimibe** | Cholesterol absorption inhibitor | Add-on if LDL goal not met on statin monotherapy | | **Bempedoic acid** | Uric acid-lowering + modest LDL reduction | Statin-intolerant patients; not first-line | | **Inclisiran** | PCSK9 inhibitor (siRNA) | Familial hypercholesterolemia or statin-intolerant; not first-line | **Clinical Pearl:** Statins also reduce triglycerides and modestly raise HDL, providing additional cardioprotection beyond LDL lowering. **Warning:** Do not confuse statin potency with choice in this scenario—all statins work; atorvastatin is chosen because it is the most widely available, cost-effective, and evidence-supported first-line agent in routine practice.